Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 856 to 870 of 1300 results for heart OR cardi* OR arrythmia

  1. Blood pressure targets for people aged over 80: What is the optimum blood pressure target for people aged over 80 with treated primary hypertension (with or without cardiovascular disease)?

    people aged over 80 with treated primary hypertension (with or without cardiovascular disease)? Any explanatory notes(if applicable) For...

    Research recommendation
    Published
    11 April 2022

  2. Further research in people who could have conventional cardiac pacemaker implantation should report the patient selection criteria and compare leadless pacemakers with conventional pacemakers. Follow-up should be for at least 5 years and outcomes should include adverse events, symptom relief, quality of life and device durability in the long-term.

    Question Further research in people who could have conventional cardiac pacemaker implantation should report the patient selection...

    Research recommendation
    Published
    12 December 2018

  3. Cardiac assessment:- What is the clinical and cost effectiveness of cardiac assessment before transplantation?

    Recommendation ID NG107/1 Question Cardiac assessment:- What is the clinical and cost effectiveness of cardiac assessment...

    Research recommendation
    Published
    18 December 2018

  4. Stopping anticoagulation after resolution of postoperative atrial fibrillation: What is the clinical and cost effectiveness of stopping anticoagulation in people whose postoperative atrial fibrillation after cardiac surgery has resolved?

    anticoagulation in people whose postoperative atrial fibrillation after cardiac surgery has resolved? Any explanatory notes(if...

    Research recommendation
    Published
    10 August 2021

  5. Education and training programmes: self-management:- What is the effectiveness and cost effectiveness of education programmes to improve information and advice and to support self-management of chronic health conditions (for example, obesity, diabetes and cardiovascular disease) for people growing older with learning disabilities, and their family members and carers?

    self-management of chronic health conditions (for example, obesity, diabetes and cardiovascular disease) for people growing older with...

    Research recommendation
    Published
    29 November 2018

  6. Further research is recommended to resolve uncertainties about the clinical effectiveness of degarelix compared with luteinising hormone-releasing hormone (LHRH) agonists such as leuprorelin, goserelin and triptorelin for treating advanced hormone-dependent prostate cancer, particularly in subgroups of people with preexisting cardiovascular disease, people with skeletal (including spinal) metastases and people with impending ureteric and urethral obstruction. Research should be planned as part of well-conducted randomised clinical trials.

    prostate cancer, particularly in subgroups of people with preexisting cardiovascular disease, people with skeletal (including spinal)...

    Research recommendation
    Published
    17 October 2016

  7. Post-operative cell salvage for patients having cardiac surgery with a significant risk of post-operative blood loss:- For patients having cardiac surgery with a significant risk of post-operative blood loss, is post-operative cell salvage and reinfusion clinically and cost effective in reducing red blood cell use and improving clinical outcomes,  compared with existing practice?

    salvage for patients having cardiac surgery with a significant risk of post-operative blood loss:- For patients having...

    Research recommendation
    Published
    11 December 2015

  8. Red blood cell transfusion thresholds for patients with chronic cardiovascular  disease:- What is the clinical and cost effectiveness of restrictive compared with liberal red blood cell thresholds and targets for patients with chronic cardiovascular disease?

    Red blood cell transfusion thresholds for patients with chronic cardiovascular disease:- What is the clinical and cost effectiveness of...

    Research recommendation
    Published
    11 December 2015

  9. Liraglutide for managing overweight and obesity (TA664)

    Evidence-based recommendations on liraglutide (Saxenda) for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults.

    Technology appraisal guidance
    Published
    9 December 2020
    View recommendations

    Sections for TA664

  10. Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (TA96)

    Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for treating chronic hepatitis B in adults.

    Technology appraisal guidance
    Published
    22 February 2006
    View recommendations

    Sections for TA96

  11. Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TA411)

    Evidence-based recommendations on necitumumab (Portrazza) for treating locally advanced or metastatic epidermal growth factor receptor (EGFR)-expressing squamous non-small-cell lung cancer in adults who have not had chemotherapy.

    Technology appraisal guidance
    Published
    28 September 2016
    View recommendations

    Sections for TA411

  12. Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)

    Evidence-based recommendations on guselkumab (Tremfya) for active psoriatic arthritis after inadequate response to DMARDs in adults.

    Technology appraisal guidance
    Published
    10 August 2022
    View recommendations

    Sections for TA815

  13. Sparsentan for treating primary IgA nephropathy (TA1074)

    Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults.

    Technology appraisal guidance
    Last updated
    9 October 2025
    View recommendations

    Sections for TA1074

  14. Pemetrexed for the treatment of malignant pleural mesothelioma (TA135)

    Evidence-based recommendations on pemetrexed for treating malignant pleural mesothelioma in adults.

    Technology appraisal guidance
    Published
    23 January 2008
    View recommendations

    Sections for TA135

  15. Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (TA1116)

    Evidence-based recommendations on obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in adults.

    Technology appraisal guidance
    Published
    11 December 2025
    View recommendations

    Sections for TA1116